Who is sponsoring NCT05592392?

NCT05592392 is sponsored by VisCardia Inc..

What drugs are being tested in NCT05592392?

Interventions in NCT05592392: Synchronized Diaphragmatic Stimulation.

What condition does NCT05592392 study?

NCT05592392 studies Heart Failure With Reduced Ejection Fraction.

Is NCT05592392 still recruiting?

NCT05592392 is currently completed. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT05592392

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RECOVER-HF Pilot Study of SDS in Heart Failure

Completed NA Last updated 22 September 2025

What this trial tests

NA trial testing Synchronized Diaphragmatic Stimulation in Heart Failure With Reduced Ejection Fraction in 35 participants. Completed in 28 February 2025.

Timeline

23 August 2022

Primary endpoint
30 September 2024

28 February 2025

Quick facts

Lead sponsor	VisCardia Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	35
Start date	23 August 2022
Primary completion	30 September 2024
Estimated completion	28 February 2025
Sites	2 locations across Georgia, Uzbekistan

Drugs / interventions tested

Synchronized Diaphragmatic Stimulation

Conditions studied

Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →

Sponsor

VisCardia Inc. — full company profile →

Who can join

18 and older, any sex, with Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RECOVER HF pilot is a feasibility study for evaluating a randomized, doubled-blinded study design to determine the benefits and risks of chronically delivering Synchronized Diaphragmatic Stimulation (SDS) in Heart Failure patients on GDMT with NYHA II/III, EF\<=40% and QRSd,=130ms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure With Reduced Ejection Fraction

Currently open trials in the same condition.

NCT07465653 — A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction · Phase 1 · recruiting
NCT07465679 — A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treat · active not recruiting
NCT07275931 — Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study · NA · recruiting
NCT06942221 — Digital Solutions in Heart Therapy (DIGNITY) · NA · recruiting
NCT07087613 — Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG · recruiting

Other VisCardia Inc. trials

Trials by the same sponsor.

NCT03484780 — VisONE Heart Failure Study: Pilot · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05592392 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VisCardia Inc.
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05592392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing